Patients with ROS1-positive NSCLC (1–2% of NSCLC patients) and BRAF-positive NSCLC (2–4% of NSCLC patients) are also commonly treated with targeted therapies: crizotinib for ROS1-rearranged NSCLC and dabrafenib with trametinib for BRAF-mutant NSCLC [17,18]. Here, BRAF is linked to non-small cell lung carcinoma.